toxylact: a07ax03 nifuroxazide
The first professional lActological database in the word
A07AX03 corresponds to nifuroxazide, an oral nitrofuran intestinal antibacterial used for acute infectious diarrhoea and colitis, designed to act locally in the gut with minimal systemic absorption. From a toxicological‑lactological standpoint, its very low oral bioavailability in adults and consequently low expected passage into breast milk support a favourable breastfeeding safety profile, although regulatory product information often remains cautious because of theoretical mutagenic concerns and limited direct lactation data.atcddd.fhi+6
ATC classification and group definition
Nifuroxazide is classified under ATC
code A07AX03 within
group A07 “Antidiarrheals, intestinal
anti‑inflammatory/anti‑infective agents”
and subgroup A07A “Intestinal antiinfectives”.wikipedia+2
The A07AX subgroup (“Other intestinal antiinfectives”)
contains locally acting
antiinfectives not falling into antibiotics (A07AA),
sulfonamides (A07AB) or
imidazole derivatives (A07AC).atcddd.fhi+1
The ATC/DDD Index lists nifuroxazide
with a Defined Daily
Dose (DDD) of 0.6 g by oral route (unit “g”,
administration route “O”) for drug
utilisation studies.iris.who+1
This DDD is a technical metric and may differ from actual
prescribed doses,
which are determined by product characteristics and
clinical guidelines.iris.who
Pharmacodynamic properties
Nifuroxazide is a nitrofuran
antibacterial that exerts broad‑spectrum
activity against common enteropathogens such as
Staphylococcus spp, Clostridium
spp, Escherichia coli, Salmonella spp and others
implicated in bacterial
diarrhoea.ingentaconnect+1
Within bacterial cells, it is metabolised to reactive
nitro intermediates that
interfere with enzyme systems involved in nucleic acid and
protein synthesis,
leading to impaired cellular function and bacterial cell
death.synapse.patsnap+1
The drug’s activity is largely confined
to the intestinal
lumen, where it reduces bacterial load and toxin
production, thereby improving
diarrhoeal symptoms and limiting local
inflammation.sciencedirect+2
Recent pharmacological reviews also describe additional
experimental properties
(anticancer, antioxidant, anti‑inflammatory effects), but
these are not part of
established clinical use for acute diarrhoea.sciencedirect
Therapeutic indications and clinical use
Clinically, nifuroxazide is indicated
for acute infectious
diarrhoea and other susceptible gastrointestinal
infections, including
traveller’s diarrhoea and colitis of bacterial
origin.drugbank+2
It is often prescribed from the onset of diarrhoea without
waiting for stool
culture results, reflecting its local action and broad
coverage of likely
bacterial pathogens.chemicalbook
Open clinical trials have shown that
orally administered
nifuroxazide can be more effective than probiotics in
treating acute diarrhoea,
with similar safety profiles.pmc.ncbi.nlm.nih
Because it acts within the gut and is poorly absorbed, it
is not used for
systemic infections; systemic antibiotics are preferred
when invasive disease
is suspected.atcddd.fhi+1
Dosage, DDD and administration
The ATC/DDD index specifies a DDD of
0.6 g nifuroxazide
orally, used primarily for comparisons of drug utilisation
across populations.atcddd.fhi+1
In practice, adult dosing commonly involves divided doses
(for example 200 mg
three times daily), with total daily doses around or
somewhat close to the DDD,
depending on national product information and formulation
strength.chemicalbook+1
Tablets or oral suspensions are used,
with treatment
durations usually limited to a few days until resolution
of symptoms.sciencedirect+1
Prolonged use is generally not recommended, both because
acute diarrhoea should
resolve and to minimise unnecessary exposure to nitrofuran
compounds.ema.europa+1
Pharmacokinetics and systemic exposure
Nifuroxazide has very low oral
bioavailability due to low or
almost zero intestinal absorption, so most of the dose
remains in the
gastrointestinal lumen and is excreted in the
faeces.e-lactation+1
This pharmacokinetic profile results in low maternal
plasma concentrations,
which in turn limit systemic exposure and potential
transfer into breast milk.e-lactation+1
Because of its poor absorption, even
drug that might reach
breast milk would face low oral bioavailability in the
infant, further reducing
systemic infant exposure, except possibly in premature
neonates with higher
intestinal permeability.medsafe+1
Regulatory documents note that it is not known whether
nifuroxazide is excreted
into human milk, but agree that any amount is likely to be
low given its
pharmacokinetics.scribd+1
Toxicological profile in adults
In adults, nifuroxazide is generally
well tolerated, with
adverse effects mostly limited to mild gastrointestinal
symptoms (nausea,
abdominal pain) and occasional hypersensitivity reactions
such as rash or
pruritus.pmc.ncbi.nlm.nih+2
Because of minimal systemic absorption, serious systemic
toxicity is uncommon
compared with fully absorbed nitrofurans; however,
nitrofuran‑class concerns
about possible mutagenic or carcinogenic potential
underlie regulatory caution
for long‑term use.scribd+1
Modern reviews highlight that
nifuroxazide has been used for
decades as an effective therapy for acute diarrhoea with a
good safety record
when limited to short courses.chemicalbook+1
Product information in some jurisdictions has been updated
to advise against
use in pregnancy and breastfeeding mainly on theoretical
grounds, not on
documented human toxicity.scribd
Lactational safety and infant risk
Lactation‑specific resources report
that nifuroxazide has
very low oral bioavailability with low or zero intestinal
absorption, making
passage into breast milk unlikely or minimal.e-lactation
Because any small amount in milk would then face low oral
bioavailability in
the infant, clinically relevant infant plasma levels are
improbable, except
possibly in premature babies or the immediate neonatal
period with higher gut
permeability.medsafe+1
On this basis, one expert database
classifies nifuroxazide
as “Very Low Risk – Compatible. Not risky for
breastfeeding or infant”, while
still advising routine infant follow‑up.e-lactation
General breastfeeding guidance notes that medicines
excreted into milk at less
than 10% of the maternal dose are usually considered
compatible, especially
when they also have low oral availability in the
infant.pmc.ncbi.nlm.nih+1
At the same time, some regulatory
assessments emphasise
theoretical mutagenic potential of nitrofuran derivatives
and recommend
avoiding nifuroxazide in pregnancy and breastfeeding as a
precaution, despite
low expected exposure.ema.europa+1
Thus, lactational risk assessments may differ:
pharmacokinetic‑based sources
tend to view it as compatible, while regulatory labelling
is more conservative
due to class effects and limited direct data.ema.europa+2
Clinical recommendations for breastfeeding women
For a breastfeeding woman with acute
infectious diarrhoea,
nifuroxazide can be considered a low‑risk option when a
locally acting
intestinal antibacterial is appropriate, particularly
given its low absorption
and low expected milk transfer.sciencedirect+1
However, clinicians should weigh this against regulatory
precautionary
statements and, where possible, consider whether
non‑antibacterial measures
(rehydration, symptomatic care) or well‑studied systemic
antibiotics compatible
with breastfeeding might suffice.breastfeedingnetwork+2
If nifuroxazide is prescribed during
lactation, use should
be limited to short courses at standard doses, while
monitoring the infant for
non‑specific gastrointestinal effects (changes in stool
pattern, vomiting) or
hypersensitivity, which are unlikely but
possible.medsafe+2
Special caution is warranted in premature or very young
neonates, where
intestinal permeability is higher; in such cases,
individualised assessment may
favour alternative treatments or closer
monitoring.pmc.ncbi.nlm.nih+1
Counselling should explain that
available pharmacokinetic
and expert data suggest minimal infant exposure and low
risk, yet regulatory
agencies maintain caution mainly for theoretical
reasons.scribd+2
As with all medicines in lactation, the general principles
of using the lowest
effective dose for the shortest duration and avoiding
unnecessary polypharmacy
apply.pmc.ncbi.nlm.nih+1
Educational summary for practice
A07AX03 nifuroxazide is a locally
acting nitrofuran
intestinal antibacterial with a DDD of 0.6 g orally,
widely used for acute
bacterial diarrhoea and related gastrointestinal
infections.wikipedia+3
Its very low oral bioavailability, low systemic
absorption, and consequently
low expected passage into breast milk underpin a
favourable toxicological‑lactological
profile, although conservative product information
reflects theoretical
mutagenicity concerns rather than documented breastfeeding
harm.ema.europa+2
In toxicological‑lactological practice,
nifuroxazide can
generally be regarded as compatible with breastfeeding for
short‑term use,
especially when guided by careful clinical judgement and
infant monitoring.pmc.ncbi.nlm.nih+2
Healthcare professionals should integrate ATC
classification, pharmacology,
pharmacokinetics, and regulatory guidance to provide
nuanced, evidence‑based
counselling to breastfeeding mothers requiring treatment
for acute infectious
diarrhoea.sciencedirect+2



